Fig. 2From: Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany≥ 50% and ≥ 30% response rates in MHD a and MMD b at third month of treatment. The asterisk (*) is used to indicate P < 0.05. MHD: monthly headache days, MMD: monthly migraine daysBack to article page